Citadel Advisors
SNDX icon

Citadel Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Citadel Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
64,200
+17,100
+36% +$372K ﹤0.01% 6707
2025
Q4 		$990K Sell
47,100
-22,000
-32% -$384K ﹤0.01% 7414
2025
Q3 		$1.06M Buy
69,100
+15,000
+28% +$196K ﹤0.01% 7408
2025
Q2 		$507K Buy
54,100
+34,300
+173% +$378K ﹤0.01% 8593
2025
Q1 		$243K Sell
19,800
-21,500
-52% -$303K ﹤0.01% 10054
2024
Q4 		$546K Sell
41,300
-12,500
-23% -$214K ﹤0.01% 8359
2024
Q3 		$1.04M Buy
53,800
+22,700
+73% +$469K ﹤0.01% 6800
2024
Q2 		$638K Sell
31,100
-22,600
-42% -$473K ﹤0.01% 7537
2024
Q1 		$1.28M Sell
53,700
-80,100
-60% -$1.79M ﹤0.01% 6428
2023
Q4 		$2.89M Sell
133,800
-184,600
-58% -$2.84M ﹤0.01% 4701
2023
Q3 		$4.62M Buy
318,400
+315,400
+10,513% +$5.97M ﹤0.01% 3782
2023
Q2 		$62.8K Sell
3,000
-13,000
-81% -$271K ﹤0.01% 11534
2023
Q1 		$338K Sell
16,000
-200
-1% -$4.97K ﹤0.01% 9134
2022
Q4 		$412K Buy
+16,200
New +$378K ﹤0.01% 8639
2021
Q3 		– Sell
-42,200
Closed -$725K – 14585
2021
Q2 		$725K Sell
42,200
-25,400
-38% -$465K ﹤0.01% 9175
2021
Q1 		$1.51M Buy
67,600
+5,500
+9% +$124K ﹤0.01% 7081
2020
Q4 		$1.38M Buy
62,100
+50,400
+431% +$1.05M ﹤0.01% 6107
2020
Q3 		$173K Sell
11,700
-800
-6% -$12.2K ﹤0.01% 8920
2020
Q2 		$185K Buy
+12,500
New +$190K ﹤0.01% 8587
2020
Q1 		– Sell
-17,700
Closed -$155K – 10125
2019
Q4 		$155K Sell
17,700
-65,800
-79% -$483K ﹤0.01% 8343
2019
Q3 		$624K Buy
+83,500
New +$761K ﹤0.01% 6378
2019
Q1 		– Sell
-44,500
Closed -$198K – 9829
2018
Q4 		$198K Buy
44,500
+24,800
+126% +$136K ﹤0.01% 7876
2018
Q3 		$159K Buy
19,700
+2,800
+17% +$20K ﹤0.01% 8356
2018
Q2 		$119K Buy
+16,900
New +$166K ﹤0.01% 8166

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Citadel Advisors's SNDX Position: Q1 2026 in Review

Citadel Advisors increased its Syndax Pharmaceuticals (SNDX) stake by 243% in Q1 2026, buying an estimated $9.71M and bringing the position to 630,942 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Citadel Advisors first reported a position in SNDX in Q2 2018 and has held it in 29 quarters since. The position peaked at $49.9M in Q1 2021. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Citadel Advisors held 630,942 shares of Syndax Pharmaceuticals worth $14.7M as of Q1 2026.
  • Citadel Advisors bought 446,939 Syndax Pharmaceuticals shares in Q1 2026, an estimated $9.71M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2707 holding.
  • Citadel Advisors first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Syndax Pharmaceuticals position peaked at $49.9M in Q1 2021.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.